Astellas set for more Vesomni approvals after Netherlands nod
This article was originally published in Scrip
Executive Summary
Astellas Pharma has secured marketing authorisation for its combination urology drug, Vesomni, in its first market, the Netherlands, which will now act as the reference member state for further approvals throughout Europe under the mutual recognition procedures.